ProCE Banner Activity

KEYLYNK-009: Phase II Trial of Maintenance Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy in Untreated Metastatic or Locally Recurrent Inoperable TNBC

Conference Coverage

Following induction therapy with pembrolizumab plus chemotherapy, maintenance therapy with pembrolizumab plus olaparib did not improve PFS or OS vs continuing pembrolizumab plus chemotherapy in patients with untreated metastatic or locally recurrent inoperable TNBC.

Released: December 07, 2023


Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Merck Sharp & Dohme, LLC

Seagen Inc.